Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › BCAX

Bicara Therapeutics

BCAX Lead: Phase 2 2 Biotech Distilled articles ↓ 17 filings & releases ↓ Cash $96.6M (Jun 30, 2026) ↓ 2 verdicts ↓ 2 timing quotes ↓
Oncology Protein

Market cap $572M 66.2M shares (10-Q, Aug 6, 2026) × $8.65 close Nov 6, 2026

Most recent annual filing: 2026-03-30

Catalyst timeline

5 trackedQuarter catalyst calendar →
  1. Ficerafusp alfa Ph1 interim2H 2026Ficerafusp alfa Ph1 interim, 2H 2026, notable
  2. Ficerafusp alfa enrollment done4Q 2026Ficerafusp alfa enrollment done, 4Q 2026, notable
  3. Ficerafusp alfa interimMid-2027Ficerafusp alfa interim, Mid-2027, major
  4. '968 Patent PTAB Review FDAJul 14, 2027'968 Patent PTAB Review FDA, Jul 14, 2027, material
  5. Ficerafusp alfa FDA approval2028Ficerafusp alfa FDA approval, 2028, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

Capital (as filed)

Cash
$96.6M cash and cash equivalents · Jun 30, 2026 (10-Q)
Short-term investments
$401M Jun 30, 2026
Operating cash flow
−$44.2M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$497M cash, runway 1H 2029 per the update of Aug 11, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (2)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (2 calls)

Every verdict Biotech Distilled has published on Bicara Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-05-30 Watch Bicara Therapeutics (BCAX) — Scientific Deep Dive for Ficerafusp Alfa and Pipeline Products Genuinely de-risked small cap with elite balance sheet, real global Phase 3, Breakthrough designation, and live takeout optionality, but efficacy thesis is still single-arm and open-label with a better-funded competitor ahead.
  2. 2026-08-12 Watch UPDATE: Bicara Therapeutics (BCAX) - Everyone Changes Chairs Before the Binary Balance sheet, trial, and M&A logic remain intact and PTAB institution improves the patent overhang picture, but efficacy case is still single-arm open-label and leadership bench will be substantially new by the time the interim prints.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (2 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (17)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jul 28, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

12 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)